• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

byAliya Ramjaun
July 11, 2019
in Chronic Disease, Dermatology
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously at weeks 0 and 4, or 80 mg of adalimumab subcutaneously, and then 40 mg at weeks 1, 3, 5 and every other week thereafter during a 16-week treatment period to evaluate the efficacy and safety of risankizumab compared with adalimumab in this patient population. After 16 weeks, adalimumab intermediate responders were re-randomized to receive either continue 40 mg adalimumab or to switch to 150 mg risankizumab. Researchers found that at 16 weeks of follow-up, a 90% reduction in Psoriasis Area and Severity Index (PASI-90) was achieved in 72% of patients in the risankizumab group and in 47% of patients given adalimumab (difference 24.9%, 95% CI 17.5% to 32.4%, p<0.0001). In addition sPGA (static Physician Global Assessment) scores of 0 or 1 were achieved in 84% of patients given risankizumab, compared to 60% of patients in the adalimumab group (difference 23.3%, 95% CI 16.6% to 30.1%, p<0.0001). In the second part of the study, PASI-90 was observed in 66% of patients that switched to risankizumab versus 21% of patients that continued with adalimumab at 44 weeks of follow-up (difference 45.0%, 95% CI 28.9 to 61.1%, p<0.0001). The incidence of adverse events was comparable between groups. This study therefore shows that risankizumab demonstrates significantly greater efficacy compared to adalimumab in patients with moderate-to-severe plaque psoriasis, with comparable safety profile.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adalimumabchronic plaque psoriasisrisankizumab
Previous Post

Recombinant zoster vaccine reduced incidence of herpes zoster in autologous stem cell transplant recipients

Next Post

Quick Take: Trends in diverting loop ileostomy vs. total abdominal colectomy as surgical management for Clostridium Difficile colitis

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa
StudyGraphics

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

December 23, 2021
#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa
StudyGraphics

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

September 8, 2021
Brodalumab effective in treating active psoriatic arthritis
Chronic Disease

Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment

May 10, 2021
Next Post
Molecular testing for Clostridium difficile may not predict disease activity

Quick Take: Trends in diverting loop ileostomy vs. total abdominal colectomy as surgical management for Clostridium Difficile colitis

#VisualAbstract: Association of Step Volume and Intensity With All-Cause Mortality in Older Women

#VisualAbstract: Association of Step Volume and Intensity With All-Cause Mortality in Older Women

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Quick Take: Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.